The Serum HER-2/neu Test and Metastatic Breast Cancer
Serum HER-2/neu: Helping Women with Metastatic Breast Cancer
The Serum HER-2/neu test is a simple blood test for over 150,000 women living with metastatic breast cancer.1 For the thousands of women diagnosed with metastatic breast cancer each year, the Siemens Serum HER-2/neu test is the only Serum HER-2/neu test available for sale in the U.S. for monitoring their Serum HER-2/neu status during therapy. The Serum HER-2/neu test is indicated for monitoring patients with metastatic breast cancer and initial serum level >15 ng/ml.
Serum HER-2/neu Status: Providing Critical Information for Metastatic Disease Assessment
Decreasing levels of Serum HER-2/neu reflect treatment response or disease stability. Increasing levels of Serum HER-2/neu reflect disease progression.*
Monitoring Serum HER-2/neu levels yields important information about response to therapy and cancer progression, and may help physicians make more informed decisions when developing and modifying patient treatment regimen. 2-4
* For the ADVIA Centaur® system a point-to-point increase or decrease of 15% reflects response or progression.
1 Silent Voices: Women with Advanced (Metastatic) Breast Cancer Share Their Needs and Preferences for Information, Support and Practical Resources.. Living Beyond Breast Cancer. 2006. Pg. 1.
2 Schwartz MK, et al. International Journal of Biological Markers 2000;15(4):324.
3 Lipton A, et al. Journal of Clinical Oncology 2002;20(6):1467.
4 Esteva FJ, et al. Journal of Clinical Oncology 2002.